Literature DB >> 23964112

Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.

Young Ki Lee1, Hyun Jung Jun, Ji Hae Nahm, Tae Seop Lim, Ji Soo Park, Joong Bae Ahn, Sun Young Rha, Hyun Cheol Chung, Hwa Eun Oh, Ji-Sun Song, Woo Ick Yang, Hyo Song Kim.   

Abstract

OBJECTIVE: Well-differentiated papillary mesothelioma is an uncommon subtype of mesothelioma with a frequently indolent course, although it occasionally manifests in a more aggressive form. To establish a treatment strategy for this rare disease, we report the clinical characteristics and outcomes of 15 patients with well-differentiated papillary mesothelioma.
METHODS: All pathologically diagnosed well-differentiated papillary mesothelioma cases were reviewed between 1998 and 2012.
RESULTS: Of the 15 cases, 8 and 7 presented with single and multiple lesions, respectively. All cases with single lesions were asymptomatic, while 4 out of the 7 cases with multiple lesions were symptomatic. After tumor excision, none of the eight single-lesion cases experienced tumor recurrence. Among the other seven cases with multiple lesions, only one patient with disseminated lesions died due to disease burden. Five patients with multiple lesions received cisplatin-based intravenous or intraperitoneal chemotherapy, with a mix of complete (n= 2) and partial (n= 2) responses observed. Of particular note, one patient receiving cisplatin and pemetrexed combination chemotherapy experienced complete tumor resolution without any serious toxicity.
CONCLUSIONS: We recommend different treatment strategies based on the disease status. If the tumor is completely resectable, an excisional biopsy seems to be sufficient. If complete resection is unavailable for the asymptomatic patient with a localized tumor extent, close follow-up is an appropriate option. When the tumor is extensive or accompanied by symptoms, chemotherapy should be strongly considered.

Entities:  

Keywords:  chemotherapy; cisplatin; pemetrexed; peritoneum; therapeutic strategy; well-differentiated papillary mesothelioma

Mesh:

Substances:

Year:  2013        PMID: 23964112     DOI: 10.1093/jjco/hyt117

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

Review 1.  The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.

Authors:  Bradley Carlson; Carla Harmath; Kiran Turaga; Hedy L Kindler; Samuel G Armato; Christopher Straus
Journal:  Abdom Radiol (NY)       Date:  2022-03-07

2.  A Case of Well-Differentiated Papillary Mesothelioma of the Male Peritoneum: Successful Treatment by Systemic Chemotherapy.

Authors:  Aziz Bazine; Mohamed Fetohi; Tariq Namad; Asmae Benzekri; Brahim Zainoun; Rachid Tanz; Mohamed Ichou
Journal:  Cureus       Date:  2017-03-19

3.  Challenging and uncommon diagnosis of long-evolution ascites.

Authors:  Marta Gravito-Soares; Elisa Gravito-Soares; João Almeida; João Fraga; Luis Tomé
Journal:  BMJ Case Rep       Date:  2017-12-02

4.  Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.

Authors:  Meredith Stevers; Joseph T Rabban; Karuna Garg; Jessica Van Ziffle; Courtney Onodera; James P Grenert; Iwei Yeh; Boris C Bastian; Charles Zaloudek; David A Solomon
Journal:  Mod Pathol       Date:  2018-08-31       Impact factor: 7.842

5.  Synchronous presentation of muscle-invasive urothelial carcinoma of bladder and peritoneal malign mesothelioma.

Authors:  Cem Basatac; Fatma Aktepe; Sezer Sağlam; Haluk Akpınar
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

6.  Peritoneal well-differentiated papillary mesothelioma associated with infertility in a 37-year-old woman.

Authors:  Bo Pang; Cong Hu; Qian Liu; Jinyu Yu; Zhentong Wei; Xiaowei Yu
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.